Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor?

Camillo Almici, MD, Francesca Fontana, Giovanna Piovani, Piera Balzarini, Arabella Neva, Benedetto Bruno, MD, Cristina Skert, GianLuca Rotta, Simona Fisogni, MD, Rosanna Verardi, Andrea Bianchetti, Simona Braga, Michele Malagola, MD, Nicolò Manaresi, PhD, Fabio Facchetti, Mirella Marini, MD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 4885.

https://doi.org/10.1182/blood-2019-121879

Published: 2019

Journal Articles

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Nicola Bianchetti, Alessandra Tucci, Alessandro Re, MD, Chiara Pagani, MD, Chiara Cattaneo, MD, Maria Miscio, Fabio Facchetti, Simona Fisogni, MD, Piera Balzarini, Domenico Albano, Giovanni Bosio, Francesco Bertagna, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2018-99-119090

Published: 2018

Journal Articles

Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

Blood (2018) 132 (Supplement 1): 5294.

https://doi.org/10.1182/blood-2018-99-116437

Published: 2018

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Alessandra Tucci, MD, Anna Guidetti, MD, Anna Dodero, MD, Francesca Schieppati, MD, Alessandro Re, MD, Nicola Bianchetti, MD, Chiara Bottelli, MD, Angela Passi, MD, Maria Miscio, Simona Fisogni, MD, Piera Balzarini, Fabio Facchetti, MD, Paolo Corradini, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 4154.

https://doi.org/10.1182/blood.V130.Suppl_1.4154.4154

Published: 2017

Journal Articles

Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)

Francesca Schieppati, MD, Simona Fisogni, MD, Piera Balzarini, PhD, Alessandro Re, MD, Luisa Lorenzi, MD, Daniela Dalceggio, MD, Angela Passi, MD, Chiara Cattaneo, MD, Fabio Facchetti, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2016) 128 (22): 5295.

https://doi.org/10.1182/blood.V128.22.5295.5295

Published: 2016

NARROW

Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor?

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)

Email alerts

ASH Publications

American Society of Hematology

Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor?

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Cell-of-Origin Identification and Prognostic Correlation in HIV-Associated Diffuse Large B-Cell Lymphomas: Results of an Italian Multicentric Study

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) As First-Line Treatment in Patients with Double-Hit Lymphoma: Preliminary Results in 35 Consecutive Patients from Two Institutions

Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only